Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIORCHESTRA CO., LTD. is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This prosecution activity is assigned to 1 distinct examiner, indicating a focused and limited scope of active patent office engagement. The involvement of 1 distinct art unit suggests that the company's current filings are concentrated within a specific technical niche of the pharmaceutical industry, rather than being spread across multiple review groups.
The busiest examiner for the portfolio is KONOPKA, CATHERINE ANNE, who is overseeing 1 busiest examiner pending office action. As the total count of pending office actions is 1, this examiner is responsible for the entirety of the company's active prosecution workload. This creates a highly focused interaction where the company's immediate patent outcomes are tied to a single examiner's review. For practitioners, this profile shows a very simple prosecution landscape with no current diversification across different examiners or art units in the Biotechnology & Pharmaceuticals field at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259007 | USE OF MIRNA-485 INHIBITORS FOR INDUCING HAIR GROWTH | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259007 | USE OF MIRNA-485 INHIBITORS FOR INDUCING HAIR GROWTH | KONOPKA, CATHERINE ANNE | 1635 | §112 | Non-Final OA | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial